Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bissonnette

Showing results (141-150 of 222) with videos related to

Pageof 23
Sort By:
Journal of the American Academy of Dermatology|June 30, 2022
One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trialBruce Strober, Linda Stein Gold, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|November 16, 2024
FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasisLaura K Ferris, Jerry Bagel, Yu-Huei Huang, et al.
Journal of the American Academy of Dermatology|August 29, 2024
A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvementMark Lebwohl, Michael Bukhalo, Linda Stein Gold, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|February 16, 2022
Systemic Therapy for Atopic Dermatitis in Older Adults and Adults With Comorbidities: A Scoping Review and International Eczema Council SurveyAaron M Drucker, Megan Lam, Carsten Flohr, et al.
The Journal of Investigative Dermatology|November 20, 2025
Ruxolitinib cream demonstrated rapid reductions in itch and atopic dermatitis signs that correlated with biomarkersRobert Bissonnette, Etienne Saint-Cyr Proulx, Joel Correa da Rosa, et al.
The British Journal of Dermatology|April 20, 2022
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitisEric L Simpson, Robert Bissonnette, Amy S Paller, et al.
The Journal of Allergy and Clinical Immunology|July 26, 2020
Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasisHelen He, Robert Bissonnette, Jianni Wu, et al.
The Journal of Rheumatology|July 17, 2015
Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity InitiativeCamille Roubille, Vincent Richer, Tara Starnino, et al.
Annals of the Rheumatic Diseases|March 11, 2015
Response to: 'drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?' by Dr BoersCamille Roubille, Vincent Richer, Tara Starnino, et al.
Annals of the Rheumatic Diseases|January 7, 2015
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysisCamille Roubille, Vincent Richer, Tara Starnino, et al.
Pageof 23

Showing results (141-150 of 222) with videos related to

Sort By:
Pageof 23
Journal of the American Academy of Dermatology|June 30, 2022
One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trialBruce Strober, Linda Stein Gold, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|November 16, 2024
FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasisLaura K Ferris, Jerry Bagel, Yu-Huei Huang, et al.
Journal of the American Academy of Dermatology|August 29, 2024
A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvementMark Lebwohl, Michael Bukhalo, Linda Stein Gold, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|February 16, 2022
Systemic Therapy for Atopic Dermatitis in Older Adults and Adults With Comorbidities: A Scoping Review and International Eczema Council SurveyAaron M Drucker, Megan Lam, Carsten Flohr, et al.
The Journal of Investigative Dermatology|November 20, 2025
Ruxolitinib cream demonstrated rapid reductions in itch and atopic dermatitis signs that correlated with biomarkersRobert Bissonnette, Etienne Saint-Cyr Proulx, Joel Correa da Rosa, et al.
The British Journal of Dermatology|April 20, 2022
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitisEric L Simpson, Robert Bissonnette, Amy S Paller, et al.
The Journal of Allergy and Clinical Immunology|July 26, 2020
Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasisHelen He, Robert Bissonnette, Jianni Wu, et al.
The Journal of Rheumatology|July 17, 2015
Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity InitiativeCamille Roubille, Vincent Richer, Tara Starnino, et al.
Annals of the Rheumatic Diseases|March 11, 2015
Response to: 'drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?' by Dr BoersCamille Roubille, Vincent Richer, Tara Starnino, et al.
Annals of the Rheumatic Diseases|January 7, 2015
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysisCamille Roubille, Vincent Richer, Tara Starnino, et al.
Pageof 23